NCT06193616View on ClinicalTrials.gov

Outcome of ADPKD With Octreotide LAR

Active, not recruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Autosomal Dominant Polycystic Kidney
Interventions
DRUG

Octreotide

All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.

Trial Locations (1)

24100

ASST HPG23 - Unità di Nefrologia, Bergamo

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT06193616 - Outcome of ADPKD With Octreotide LAR | Biotech Hunter | Biotech Hunter